AF
QNCX icon

Amalgamated Financial’s Quince Therapeutics QNCX Stock Holding History

Amalgamated Financial’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$20K Buy
+16
New +$21.8K ﹤0.01% 2752

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amalgamated Financial's QNCX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Quince Therapeutics (QNCX) in Q1 2022: 16 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #2752 among its holdings.

85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • Amalgamated Financial held 16 shares of Quince Therapeutics worth $20K as of Q1 2022.
  • Quince Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Quince Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2752 holding.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.